Hologic, Inc. $HOLX Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 22.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,606 shares of the medical equipment provider’s stock after selling 7,320 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Hologic were worth $1,668,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Chung Wu Investment Group LLC acquired a new position in shares of Hologic in the 2nd quarter worth approximately $26,000. Zions Bancorporation National Association UT acquired a new position in shares of Hologic in the 1st quarter worth approximately $34,000. Cromwell Holdings LLC grew its position in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 436 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Hologic in the 1st quarter worth approximately $42,000. Finally, Allworth Financial LP grew its position in shares of Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 216 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.1%

NASDAQ:HOLX opened at $73.99 on Monday. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The firm has a market capitalization of $16.46 billion, a P/E ratio of 30.70, a P/E/G ratio of 2.54 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The business has a 50 day simple moving average of $67.65 and a 200 day simple moving average of $64.03.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HOLX. Morgan Stanley lifted their target price on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Hologic in a research report on Wednesday, October 8th. Royal Bank Of Canada upgraded Hologic from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. UBS Group boosted their price objective on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research report on Thursday, July 31st. Finally, Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $79.23.

Insider Buying and Selling at Hologic

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the sale, the director owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The disclosure for this sale can be found here. 1.88% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.